Zealand Pharma: New data from Phase 2 ZUPREME-1 trial further supports potential of petrelintide to redefine the weight management experience
- Co announces the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide, at the 2026 Scientific Sessions of the American Diabetes Association® (ADA).
- Results from the 42-week, Phase 2 trial show that participants who received once-weekly subcutaneous injections of petrelintide, an amylin analog, achieved clinically meaningful reductions in body weight compared to placebo.
- Treatment with petrelintide was associated with improvements in cardiometabolic disease risk factors and was well tolerated with rates of gastrointestinal (GI)-related adverse events (AEs) generally similar to placebo.
- Clinically meaningful, double-digit weight loss demonstrated through week 42.
- Placebo-like tolerability observed and low rates of treatment discontinuation due to gastrointestinal adverse events.
- Treatment associated with improvements in cardiometabolic disease risk factors, including reductions in waist circumference, high-sensitivity C-reactive protein and triglycerides.
- Data reinforces the potential of petrelintide to enhance treatment persistence and address current challenges of treatment durability, tolerability and acceptability.
- Phase 3 trials for chronic weight management planned for initiation in 2H26.